Company Overview and News

28
Why I Sold This 11.1% Yielding BDC That Could Now Be A 'Buy'

2018-10-11 seekingalpha - 3
FSIC was my smallest position and I sold before the recent declines for the reasons discussed in this article.
CCT AIY AINV CLA SDRPQ MCQ HRZN HTF KAP BKCC MCV BBDC OSLE MM ACTPF KCAP ABDC HTFA TSG CPTA FDMCF AST MCC GSBD HDSN TCRX GARS HCAPL MMCC FSIC TCPC AIB TCRD TCRZ PSEC SD TSLF OCSI SDOCQ OCSL MCX HCAP SDRXP PBB SDRXQ

4
SandRidge says interim CEO not in race for top job

2018-09-21 reuters
Sept 21 (Reuters) - SandRidge Energy Inc said on Friday interim Chief Executive Officer William Griffin would not be a candidate for the position of CEO.
SDOCQ SDRPQ SDRXP SD SDRXQ

4
SandRidge says interim CEO not in race for top job

2018-09-21 channelnewsasia
SandRidge Energy Inc said on Friday interim Chief Executive Officer William Griffin would not be a candidate for the position of CEO.
SDOCQ SDRPQ SDRXP SD SDRXQ

4
SandRidge says interim CEO not in race for top job

2018-09-21 reuters
(Reuters) - SandRidge Energy Inc (SD.N) said on Friday interim Chief Executive Officer William Griffin would not be a candidate for the position of CEO.
SDOCQ SDRPQ SDRXP SD SDRXQ

4
SD / Sandridge Energy Inc. 8-K (Current Report)

2018-09-21 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SD

34
Blue Ridge Mountain Resources Announces Key Executive Management Appointment

2018-09-19 globenewswire
IRVING, Texas, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Blue Ridge Mountain Resources, Inc. (OTCPK: BRMR) (“Blue Ridge” or the “Company”) today is pleased to announce the appointment of Michael Hodges to Senior Vice President of Finance. Michael’s first day with the Company will be September 19, 2018. Effective upon the successful completion of the Company’s proposed merger with Eclipse Resources Corporation (NYSE: ECR) (“Eclipse”), Michael will assume the role of Executive Vice President and Chief Financial Officer of Eclipse from Matthew DeNezza, who is currently serving in such capacity with Eclipse.
ECR CKRGZ BRMR CHKVP SDRPQ CHKDH CHKVZ SD CHKDG CHKWZ SDOCQ CHKDJ REXX CHKDP RXNRP CHK.WI CHK REXXQ SDRXP SDRXQ

28
E&P 'Bottom Of The Barrel' Club #18-5: Ex-Chapter 11 Company Stats For The First Half Of 2018

2018-09-17 seekingalpha - 3
They're baaack! Actually, some of them have been back for a while, but I have not felt compelled to write about them until now. "They" are, of course, former members of my Bottom of the Barrel Club who declared bankruptcy during the past 2-3 years. The companies in this article are now trading publicly again (with 1 or 2 exceptions). I may refer to them as the "X-11 Club" occasionally.
ECR CHPE UPL GDPMQ LNGG SDRPQ DVN PVA GDAOQ VNR CHAP VNRBP GDRRQ LINEQ TALO GDPM BRMR PVAYQ VNRR HKRCP SBOW SD GDUEQ SDOCQ GDANQ GDP RVRA PVAC SGY HK MPO VNRAP TTEN MPOYQ VNRCP UPLMQ BRY GDPAN SDRXP LINE SDRXQ GDPAQ

37
Jericho Oil Elects to Participate in Multiple STACK Wells

2018-09-13 globenewswire
TULSA, Okla. and VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Jericho Oil Corporation (“Jericho”) (TSX-V: JCO; OTC PINK: JROOF) announces that its Oklahoma STACK Joint Venture (“STACK JV”) has elected to participate in its second Meramec formation well, the Valkyrie 6-19N-12W #1H, within its Blaine County STACK acreage position. In addition to the Valkyrie, the STACK JV has also elected to participate in two additional Osage formation wells to be drilled by Exxon Mobil’s subsidiary XTO Energy and Alta Mesa Resources in Major County.
CKRGZ XOM CHKVP SDRPQ JROOF CHKDH CHKVZ XTO SD CHKDG CHKWZ SDOCQ CHKDJ CHKDP CHK.WI CHK AMR JCO SDRXP SDRXQ

4
SandRidge Energy Rejects Takeover Bids, Saying They Undervalue Company

2018-09-11 rigzone
Sept 10 (Reuters) - U.S. shale oil producer SandRidge Energy Inc said on Monday it had ended its strategic review and rejected all bids, saying they undervalued the company.
SDOCQ SDRPQ SDRXP SD SDRXQ

15
Deals of the day-Mergers and acquisitions

2018-09-11 reuters - 1
Sept 11 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Tuesday:
SDOCQ BABA SDRPQ 6723 IDTI RNECF RNECY SDRXP SD SDRXQ

4
SD / Sandridge Energy Inc. 8-K (Current Report)

2018-09-11 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SD

21
PRESS DIGEST -Wall Street Journal - Sept 11

2018-09-11 reuters
Sept 11 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
SDOCQ SDRPQ 6723 RNECF RNECY QCOM SDRXP SD SNAP SDRXQ

4
SandRidge Energy rejects takeover bids, saying they undervalue company

2018-09-11 reuters
(Reuters) - U.S. shale oil producer SandRidge Energy Inc (SD.N) said on Monday it had ended its strategic review and rejected all bids, saying they undervalued the company.
SDOCQ SDRPQ SDRXP SD SDRXQ

4
Proposal would settle Chesapeake lawsuit for $6.95 million

2018-09-06 nzherald.co.nz
OKLAHOMA CITY (AP) — A proposed $6.95 million settlement would end a lawsuit alleging the co-founders Oklahoma City-based Chesapeake Energy conspired to rig bids on leases for land to explore for oil and natural gas.
SDOCQ SDRPQ SDRXP SD SDRXQ

63
Tracking Carl Icahn's Portfolio - Q2 2018 Update

2018-09-03 seekingalpha - 6
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Carl Icahn’s Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
VLTCP CQP CVI SDRPQ FCX TPCA VMW ENZN AFNL HRI NWL EGN VLTCW CI WBT VKSC ARII LNG GLPI SD XRX IEP NAV CNDT SDOCQ HLF UAN DVMT ERI CVRR VLTC MTW SDRXP HTZ SDRXQ

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to SD / Sandridge Energy Inc. on message board site Silicon Investor.

AMERITRADE HLD A (NASDAQ:AMTD) AMERITRADE HLD A (NASDAQ:AMTD) AMERITRADE HLD A (NASDAQ:AMTD) Shopify Inc (SHOP: NASDAQ) SHOP.TO Shopify Inc (SHOP: NASDAQ) SHOP.TO Shopify Inc (SHOP: NASDAQ) SHOP.TO
PSDV - pSivida Limited PSDV - pSivida Limited PSDV - pSivida Limited Manmade Global Warming, A hoax? A Scam? or a Doomsday Cult? Manmade Global Warming, A hoax? A Scam? or a Doomsday Cult? Manmade Global Warming, A hoax? A Scam? or a Doomsday Cult?
Tuesday Morning Tuesday Morning Tuesday Morning Lam Research (LRCX, NASDAQ): To the Insiders Lam Research (LRCX, NASDAQ): To the Insiders Lam Research (LRCX, NASDAQ): To the Insiders
Aixtron AIXG now listed on the NASDAQ after GGNS merger Aixtron AIXG now listed on the NASDAQ after GGNS merger Aixtron AIXG now listed on the NASDAQ after GGNS merger Ancestry.com NASD: ACOM Ancestry.com NASD: ACOM Ancestry.com NASD: ACOM
Cardiac Science Inc. DFIB (NASDAQ) Cardiac Science Inc. DFIB (NASDAQ) Cardiac Science Inc. DFIB (NASDAQ) seadrill SDRL seadrill SDRL seadrill SDRL
CUSIP: 80007P869